This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Mesothelioma

THE FIRST AND ONLY DUAL IMMUNOTHERAPY IN 1L uMPM

View indication details

  • OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Expert opinion

Pleural Mesothelioma
State of the art in 2022
with new perspectives

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing scheme
OPDIVO+YERVOY
in 1L uMPM

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

A diary for your patients treated with
OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient brochure
with practical information
on immunotherapy

Patient alert card
OPDIVO

Useful links

1L uMPM, first-line unresected pleural mesothelioma; CT, chemotherapy irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.